Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...6061626364656667686970...123124»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial initiation date, Trial primary completion date:  PRIMER-1: Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) -  Apr 12, 2022   
    P2,  N=60, Not yet recruiting, 
    Trial completion date: Mar 2026 --> Jun 2026 | Initiation date: Mar 2022 --> Jun 2022 | Trial primary completion date: Mar 2026 --> Jun 2026
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Mismatch repair:  Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer (clinicaltrials.gov) -  Apr 12, 2022   
    P2,  N=100, Recruiting, 
    Trial completion date: Mar 2026 --> Jun 2026 | Initiation date: Mar 2022 --> Jun 2022 | Trial primary completion date: Mar 2026 --> Jun 2026 Not yet recruiting --> Recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Trial completion date, Trial primary completion date:  Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET) (clinicaltrials.gov) -  Apr 11, 2022   
    P=N/A,  N=12, Recruiting, 
    Trial completion date: Dec 2023 --> Oct 2024 | Trial primary completion date: Dec 2023 --> Oct 2024 Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Sep 2023 --> Jan 2024
  • ||||||||||  First-Line Immunotherapy-Based Combinations for Metastatic Renal Cell Carcinoma: Systematic Review and Network Meta-Analysis (Room 222) -  Apr 10, 2022 - Abstract #AUA2022AUA_1547;    
    In patients with =1% PD-L1 expression, the highest likelihood of better PFS was associated with lenvatinib plus pembrolizumab and nivolumab plus ipilimumab Conclusions : Our network meta-analysis suggests that ICI-TKI combinations provide superior PFS, ORR, and OS over ICI-ICI combinations, regardless of the IMDC risk group. However, ICI-ICI combination could be the optimal treatment for tumors with increased PD-L1 expression.
  • ||||||||||  The role of nephrectomy in metastatic renal cell carcinoma in the era of immune-combination therapies: a meta-analysis (Room 222) -  Apr 10, 2022 - Abstract #AUA2022AUA_1540;    
    ICI-combination therapy was associated with significantly better OS/PFS than sunitinib in patients who had undergone CN (hazard ratio [HR], 0.67, 95% confidence interval [CI], 0.59–0.77/HR, 0.57, 95% CI, 0.44–0.74, respectively, both P<0.001), and in those who had not (HR, 0.69, 95% CI, 0.57–0.85/ HR, 0.63, 95% CI, 0.52–0.77, respectively, both P<0.001)...In network meta-analyses, nivolumab plus cabozantinib was the most effective regimen in those undergoing CN, and pembrolizumab plus lenvatinib for those not undergoing CN...Careful patient selection remains paramount. As each ICI-combination regimen varied widely in its effect in those who had and had not undergone CN, CN may contribute to better treatment decision-making for ICI combination therapy recipients.
  • ||||||||||  lenvatinib / Generic mfg.
    Clinical, Journal:  Lenvatinib-related renal microangiopathy: a case series. (Pubmed Central) -  Apr 9, 2022   
    The best therapy in these patients is still uncertain. Earlier and more precise measurement of urine protein levels, allowing for early dose adjustment, could be effective in preventing further damage and drug discontinuation.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Clinical guideline, Journal:  SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021). (Pubmed Central) -  Apr 9, 2022   
    One third of patient with thymoma present an autoimmune disorders, increasing the risk of immune-related adverse events and autoimmune flares under ICIs. In these guidelines, we summarize the current evidence for the therapeutic approach in patients with TET and define levels of evidence for these decisions.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal, PD(L)-1 Biomarker:  Lenvatinib plus pembrolizumab: The next frontier for the treatment of hepatocellular carcinoma? (Pubmed Central) -  Apr 8, 2022   
    Recently, immune-based combinations have reported important results in advanced HCC, as witnessed by the landmark IMbrave150 trial. Based on the promising results of early phase clinical trials, lenvatinib plus pembrolizumab has the potential to represent a novel treatment option in this setting.
  • ||||||||||  Review, Journal:  Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. (Pubmed Central) -  Apr 8, 2022   
    More recently, synergistic combination therapy has boosted first-line (atezolizumab in combination with bevacizumab) and second-line (ipilimumab in combination with nivolumab) therapeutic modalities for aHCC...Additionally, we describe the promising effect of traditional Chinese medicine (TCM) as systemic therapy on HCC. In this setting, the challenges and future directions of systemic therapy for HCC are also explored.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Recent advances in immunotherapy for hepatocellular carcinoma. (Pubmed Central) -  Apr 7, 2022   
    However, challenges such as low response rate and acquired resistance in previously respondent patients still exist. Further research is needed to understand the unique resistance mechanism to immunotherapy and to discover more predictive biomarkers to guide clinical decision making.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial initiation date, Metastases:  MK-3475-A70: Pembrolizumab and Lenvatinib in Advanced Cervical Cancer (clinicaltrials.gov) -  Apr 7, 2022   
    P2,  N=35, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Mar 2022 Initiation date: Mar 2022 --> Jun 2022
  • ||||||||||  Mekinist (trametinib) / Novartis, Keytruda (pembrolizumab) / Merck (MSD), Tafinlar (dabrafenib) / Novartis
    Journal, PD(L)-1 Biomarker:  Mutation Based Approaches to the Treatment of Anaplastic Thyroid Cancer. (Pubmed Central) -  Apr 6, 2022   
    Therefore, this value may have utility as a surrogate marker for estimating the oncological aggressiveness of tumors and their associated prognosis. The integration of early genomic analysis and personalized neoadjuvant TKI therapy into the treatment of ATC can greatly benefit patient care outcomes and optimize tumour control.
  • ||||||||||  lenvatinib / Generic mfg.
    Retrospective data, Journal:  Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib. (Pubmed Central) -  Apr 5, 2022   
    Multivariate analysis revealed that pre-existing proteinuria at baseline (hazard ratio (HR), 9.72; 95% confidence interval (CI), 1.29-52.21; p = 0.030), and eGFR <60 mL/min/1.73 m at baseline (HR, 4.49; 95% CI, 1.32-16.07; p = 0.017) were significantly associated with developing grade ≥2 proteinuria. These patients should be monitored carefully, and our preliminary data should be confirmed by further studies.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker:  Advances in targeted therapy for anaplastic thyroid carcinoma. (Pubmed Central) -  Apr 5, 2022   
    The mammalian target of rapamycin pathway inhibitors, peroxisome proliferators-activated receptor γ agonists, endothelial growth factor receptors-targeting monoclonal antibody cetuximab and novel vascular blocker fosbretabulin are still in the clinical research stage, which are expected to provide new directions for the development of novel targeted drugs. This article reviews the current research progress on targeted drugs for the treatment of ATC.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker:  Predictive biomarkers for systemic therapy of hepatocellular carcinoma. (Pubmed Central) -  Apr 2, 2022   
    In recent years, several systemic therapy drugs including sorafenib, lenvatinib, regorafenib, cabozantinib, ramucicurab, nivilumab, and pembrolizumab have been approved by FDA for advanced HCC...: There are still limited clinically applicable and validated predictive biomarkers to identify HCC patients who benefit from systemic therapy. Further prospective biomarker validation studies for HCC personalized systemic therapy are required.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal, PD(L)-1 Biomarker, IO biomarker:  Recent pharmacological approaches for the treatment of renal cell carcinoma. (Pubmed Central) -  Apr 1, 2022   
    The CheckMate 214 trial investigated the combination of nivolumab (a programmed cell death protein 1 [PD-1] inhibitor) and ipilimumab (a cytotoxic T-lymphocyte antigen-4 [CTLA-4)] inhibitor)...These combinations are: 1) pembrolizumab (PD-1 inhibitor) plus axitinib, 2) nivolumab plus cabozantinib, and 3) pembrolizumab plus lenvatinib...Predictive biomarkers and new therapeutic approaches are urgently needed to overcome treatment failures. A growing understanding of immune escape mechanisms and the interplay between the immune response and the gut microbiota may offer additional rescue strategies beyond ICIs and TKIs.
  • ||||||||||  Opdivo (nivolumab) / BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Trial completion date, Trial primary completion date:  IMMUNIB: Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma (clinicaltrials.gov) -  Mar 31, 2022   
    P2,  N=50, Active, not recruiting, 
    A growing understanding of immune escape mechanisms and the interplay between the immune response and the gut microbiota may offer additional rescue strategies beyond ICIs and TKIs. Recruiting --> Active, not recruiting | Trial completion date: May 2022 --> Mar 2023 | Trial primary completion date: Feb 2022 --> Nov 2022